Bortezomib (VELCADE®) in metastatic breast cancer: Pharmacodynamics, biological effects, and prediction of clinical benefits

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 813-817

  Yang, C H ^a   Gonzalez Angulo, A M ^a   Reuben, J M ^a   Booser, D J ^a   Pusztai, L ^a   Krishnamurthy, S ^a   Esseltine, D ^b   Stec, J ^b   Broglio, K R ^a   Islam, R ^a   Hortobagyi, G N ^a   Cristofanilli, M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

Bortezomib; Breast cancer; Proteasome inhibitor; Velcade

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PROTEASOME; PROTEIN P70; TAXANE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; BORONIC ACID DERIVATIVE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE;

AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD TOXICITY; BLURRED VISION; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DESQUAMATION; DIARRHEA; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG RESPONSE; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVITY; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; LEUKOPENIA; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSORY NEUROPATHY; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; ADULT; BONE TUMOR; BREAST TUMOR; DISEASE FREE SURVIVAL; FEMALE; MALE; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; PATHOLOGY; PLEURA TUMOR; SOFT TISSUE TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; BONE NEOPLASMS; BORONIC ACIDS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PLEURAL NEOPLASMS; PROTEASE INHIBITORS; PYRAZINES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 33646186160     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj131     Document Type: Article

References (24)

1. Jemal A, Murray T, Ward E et al. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
2. Mincey BA, Perez EA. Advances in screening, diagnosis, and treatment of breast cancer. Mayo Clin Proc 2004; 79: 810-816.
3. Hortobagyi GN. Chemotherapy of breast cancer: A historical perspective. Semin Oncol 1997; 24: S17-11-S17-14.
4. Honig S. Treatment of metastatic disease. In Harris J, Lippman M, Morrow M (eds): Diseases of the breast, Philadelphia: Lippincott-Raven 1996; 669-734.
5. Falkson CI. Treatment of metastatic malignant melanoma. Anticancer Drugs 1995; 6: 709-716.
6. Adams J, Palombella VJ, Sausville EA et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-2622.
7. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
8. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
9. Sunwoo JB, Chen Z, Dong G et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-1428.
10. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
11. Lightcap ES, McCormack TA, Pien CS et al. Proteasome inhibition measurements: Clinical application. Clin Chem 2000; 46: 673-683.
12. Shah MH, Young D, Kindler HL et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10: 6111-6118.
13. Papandreou CN, Daliani DD, Nix D et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-2121.
14. Blaney SM, Bernstein M, Neville K et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004; 22: 4804-4809.
15. Albenell J, baselga J, Guix M et al. Phase I study of bortezomib in combination with docetaxel in anthrcycline-pretreated advanced breast cancer. Proc Am Soc Clin Oncol 22:16 (abstr. 63), 2003; 16.
16. Dees E, O'Neil B, Humes E et al. Phase I clinical trial of the proteasome inhibitor bortezomib in combination with pegylated liposomal doxorubicin in patients with refractory solid tumors. In (ed) (eds): Proc Am Soc Clin 22:217 (Abstr 868), 2004.
17. Bachelot T, Ray-Coquard I, Menetrier-Caux C et al. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88: 1721-1726.
18. Orlowski RZ, Stinchcombe TE, Mitchell BS et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-4427.
19. Adams J. Proteasome inhibition in cancer: Development of PS-341. Semin Oncol 2001; 28: 613-619.
20. Goy A, Younes A, McLaughlin P et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675.
21. Agterof MJ, Biesma DH. Images in clinical Medicine. Bortezomib-induced skin lesions. N Engl J Med 2005; 352: 2534.
22. Swenerton KD, Legha SS, Smith T et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 1979; 39: 1552-1562.
23. Rizzieri DA, Vredenburgh JJ, Jones R et al. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell support. J Clin Oncol 1999; 17: 3064-3074.
24. Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.